The molecule used to deliver an intervention to a cell can differ from the target of the treatment that cell produces. Both targeting steps need to be named.
A primary mouse cardiac-fibrosis study used CD5-targeted lipid nanoparticles to deliver RNA encoding a receptor directed against fibroblast activation protein. CD5 specified a delivery interaction; the encoded receptor had a different recognition target. This is a non-oncology preclinical illustration of the distinction, not cancer-treatment evidence. Delivery, expression, effector recognition and clinical benefit should retain their separate experiments and biological settings.
Targeted-LNP studies show three separate questions. Which cells receive usable cargo: in the CD5 study mRNA reached most cultured mouse T cells (83 per cent expressed the receptor, against 7 per cent with isotype-control particles) and receptor expression appeared across the main T-cell subsets in injured mice, while liver expression occurred with both CD5 and control particles; recombination in a Cre reporter reached 81.1 per cent of CD4-positive and 75.6 per cent of CD8-positive splenocytes but also 15.0 per cent of CD3-negative cells, and the statement that 87 per cent of receptor-positive cells were CD4-positive is a share of expressing cells, not the share of CD4 T cells that expressed the receptor, so each percentage needs its denominator. What the receptor recognises: FDA's January 2024 CAR T guidance says cytokine release and killing should be antigen-dependent, testable with cells that vary in target antigen expression, and asks sponsors to assess targeting of healthy tissue that expresses the intended antigen (on-target, off-tumour) and of other antigens (off-target); activity against antigen-positive healthy cells would therefore show target-dependent activity and a safety concern, not selective cancer killing. Where engineered cells act is a further question: a later study with targeted lipid nanoparticles reports reprogrammed CD8-positive T cells from healthy donors and autoimmune patients, tumour control in humanised mice and B-cell depletion in cynomolgus monkeys, each a different experiment and setting (Hunter and colleagues; abstract only). For a vaccine the address can instead be an antigen-presenting cell: intravenous RNA-lipoplexes were aimed at dendritic cells and macrophages in lymphoid compartments by adjusting net charge, without a molecular ligand (Kranz and colleagues).
Shares Binders as targeting modules, Immune measurements and product evidence.
Shares Messenger RNA construct anatomy, Immune measurements and product evidence.
Shares Messenger RNA construct anatomy, Immune measurements and product evidence.
Shares Binders as targeting modules, Immune measurements and product evidence.
Shares Messenger RNA construct anatomy, Immune measurements and product evidence.
Shares Binders as targeting modules, Immune measurements and product evidence.
Shares Messenger RNA construct anatomy, Immune measurements and product evidence.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/